Spennende ting på gang
Det er mye spennende på gang i Circio, og jeg tror det er lurt å følge denne aksjen fremover. Selskapet har innledet et svært spennende klinisk samarbeid med Oslo Universitetssykehus for å teste ut behandling av beinmargskreft med kreftvaksinen TGO1. Lykkes Circio med denne vaksinen er oppsiden formidabel. Per i dag finnes det nemlig ingen god alternativ behandling for pasienter med kreft i bukspyttkjertelen.
SomSa
08.11.2024 kl 11:48
151
Når Atlas er tomt må fylles på nytt siden kassen til Circio eller tidligere Targovax tømmes etter kort tid.
Sukiyaki
08.11.2024 kl 11:17
178
Gullhaugen skrev Atlas er tom nå.
Det har kontoen til CRNA vært i mange år.
un520
26.05.2024 kl 13:40
988
Og her er oversikten for Circio (15.april)
HØSE AS
587 589
21,89%
7,25%
ORD
NOR
Nordnet Bank AB
269 919
10,05%
3,33%
NOM
SWE
BÆKKELAGET HOLDING AS
200 018
7,45%
2,47%
ORD
NOR
SKOTHEIM
178 452
6,65%
2,20%
ORD
NOR
PETTERSEN
155 542
5,79%
1,92%
ORD
NOR
SKIPPERUD
121 000
4,51%
1,49%
ORD
NOR
SELSBAK
116 900
4,35%
1,44%
ORD
NOR
LUNDE
111 111
4,14%
1,37%
ORD
NOR
NCS ENERGY CONSULTANTS AS
110 000
4,10%
1,36%
ORD
NOR
BRETTEL ØKONOMI AS
108 000
4,02%
1,33%
ORD
NOR
NORDNET LIVSFORSIKRING AS
100 504
3,74%
1,24%
ORD
NOR
VAKTMESTERGRUPPEN AS
96 758
3,60%
1,19%
ORD
NOR
Danske Bank A/S
78 353
2,92%
0,97%
NOM
DEN
RAMIC
72 696
2,71%
0,90%
ORD
NOR
Ramsvik
70 000
2,61%
0,86%
ORD
NOR
RAGNVALD GABRIELSEN AS
65 197
2,43%
0,80%
ORD
NOR
WESTERHEIM
65 000
2,42%
0,80%
ORD
NOR
GRANUM & CO AS
62 560
2,33%
0,77%
ORD
NOR
PETTERSEN GRUPPEN AS
62 367
2,32%
0,77%
ORD
NOR
LIE
52 500
1,96%
0,65%
ORD
NOR
Total number owned by top 20
2 684 466
33,10%
HØSE AS
587 589
21,89%
7,25%
ORD
NOR
Nordnet Bank AB
269 919
10,05%
3,33%
NOM
SWE
BÆKKELAGET HOLDING AS
200 018
7,45%
2,47%
ORD
NOR
SKOTHEIM
178 452
6,65%
2,20%
ORD
NOR
PETTERSEN
155 542
5,79%
1,92%
ORD
NOR
SKIPPERUD
121 000
4,51%
1,49%
ORD
NOR
SELSBAK
116 900
4,35%
1,44%
ORD
NOR
LUNDE
111 111
4,14%
1,37%
ORD
NOR
NCS ENERGY CONSULTANTS AS
110 000
4,10%
1,36%
ORD
NOR
BRETTEL ØKONOMI AS
108 000
4,02%
1,33%
ORD
NOR
NORDNET LIVSFORSIKRING AS
100 504
3,74%
1,24%
ORD
NOR
VAKTMESTERGRUPPEN AS
96 758
3,60%
1,19%
ORD
NOR
Danske Bank A/S
78 353
2,92%
0,97%
NOM
DEN
RAMIC
72 696
2,71%
0,90%
ORD
NOR
Ramsvik
70 000
2,61%
0,86%
ORD
NOR
RAGNVALD GABRIELSEN AS
65 197
2,43%
0,80%
ORD
NOR
WESTERHEIM
65 000
2,42%
0,80%
ORD
NOR
GRANUM & CO AS
62 560
2,33%
0,77%
ORD
NOR
PETTERSEN GRUPPEN AS
62 367
2,32%
0,77%
ORD
NOR
LIE
52 500
1,96%
0,65%
ORD
NOR
Total number owned by top 20
2 684 466
33,10%
Gullhaugen
24.05.2024 kl 15:53
1287
TOP 50 bare øker og øker sist nå med 71 300 aksjer
Oversikt for CIRCA (CIRCA GROUP AS ). Oppdatert VPS 24.05.2024
01 NORSKE SKOG ASA 25.92% 35.61m 31.65m
02 SAXO BANK A/S 14.75% 20.26m 18.01m
03 CITIBANK, N.A. 11.74% 16.13m 14.34m
04 CIRCA GROUP AS 5.30% 7 280.3k 6 471k
05 DUNCAN ANTHONY JAMES 4.49% 6 165k 5 480k
06 LAWRENCE CHRISTOPHER HOWARD 3.31% 4 547.4k 4 042k
07 NORDNET LIVSFORSIKRING AS 2.21% 3 038k 2 700k 469
08 J.P. MORGAN SE 1.80% 2 475k 2 200k
09 TEAM AMERICA PTY LTD 1.45% 1 995k 1 773k
10 MOATA PTY LTD 0.98% 1 350k 1 200k
11 PERSHING LLC 0.87% 1 191.8k 1 059k
12 BMS INVEST AS 0.82% 1 125.2k 1 000k
13 LEIN ANDREAS LUDVIGSEN 0.52% 718.93k 639k ++++++36 000
14 INTERACTIVE BROKERS LLC 0.52% 709.25k 630.4k
15 HELLERUD TOR 0.49% 678.77k 603.4k
16 NORDNET BANK AB 0.44% 606.29k 538.9k -14 725
17 SKANDINAVISKA ENSKILDA BANKEN AB 0.41% 562.5k 500k
18 SKIHUS AS 0.34% 469.39k 417.2k
19 TRIVON AS 0.33% 450k 400k
20 HØGNABBEN AS 0.31% 426.38k 379k
21 MORTEN CARLSON AS 0.30% 417.18k 370.8k
22 JOHNSEN HARALD MORTEN 0.30% 410.63k 365k
23 M PAULEN HOLDING AS 0.30% 408.04k 362.7k
24 HALDEN THORLEIF 0.29% 393.75k 350k ++++++++++50 000
25 GILBO ODD AUGUST 0.28% 381.07k 338.7k
26 KLAVENESS MARINE FINANCE AS 0.27% 364.06k 323.6k
27 JØRSTAD JAN-HENRIK 0.25% 346.52k 308k
28 WINGE JØRGEN 0.25% 337.97k 300.4k
29 NORDEA BANK ABP 0.25% 337.84k 300.3k
30 THIRTY EIGHTH SEPELDA P/L ATF FINC 0.25% 337.5k 300k
31 RISA FORVALTNING AS 0.23% 315k 280k
32 PROFECTUS-INVEST AS 0.22% 308.89k 274.6k
33 LAM CONG LUONG 0.22% 303.75k 270k
34 KOLBEINSHAVN HELGE 0.21% 292.5k 260k
35 SPERRE LARS PEDER SØRVAAG 0.21% 285.25k 253.6k
36 GRINDVOLL IDAR ANDERSEN 0.21% 284.52k 252.9k
37 HERSETH AS 0.19% 258.75k 230k
38 MIDDELBOE AS 0.19% 258.75k 230k
39 TEIEN OLE ANDREAS 0.19% 256.33k 227.8k
40 HØSE AS 0.17% 238.44k 212k
41 JANSSON KRISTIAN HENRY 0.17% 234.28k 208.3k
42 SWEDBANK AB 0.17% 227.7k 202.4k
43 SIX SIS AG 0.17% 226.7k 201.5k
44 TANGERUD KJETIL KEITH 0.16% 225.52k 200.5k
45 LBM INVEST AS 0.16% 225k 200k
46 REINERTSEN INGE 0.16% 225k 200k
47 T.M.C INVEST AS 0.16% 225k 200k
48 CARLSON MORTEN ALF 0.15% 210.6k 187.2k
49 BRAATHEN JØRGEN HELLUM 0.15% 208.17k 185k
50 AAS GAUTE 0.15% 206.39k 183.5k
51 Other investors 16.62% 22.83m 20.29m -71 300
Oversikt for CIRCA (CIRCA GROUP AS ). Oppdatert VPS 24.05.2024
01 NORSKE SKOG ASA 25.92% 35.61m 31.65m
02 SAXO BANK A/S 14.75% 20.26m 18.01m
03 CITIBANK, N.A. 11.74% 16.13m 14.34m
04 CIRCA GROUP AS 5.30% 7 280.3k 6 471k
05 DUNCAN ANTHONY JAMES 4.49% 6 165k 5 480k
06 LAWRENCE CHRISTOPHER HOWARD 3.31% 4 547.4k 4 042k
07 NORDNET LIVSFORSIKRING AS 2.21% 3 038k 2 700k 469
08 J.P. MORGAN SE 1.80% 2 475k 2 200k
09 TEAM AMERICA PTY LTD 1.45% 1 995k 1 773k
10 MOATA PTY LTD 0.98% 1 350k 1 200k
11 PERSHING LLC 0.87% 1 191.8k 1 059k
12 BMS INVEST AS 0.82% 1 125.2k 1 000k
13 LEIN ANDREAS LUDVIGSEN 0.52% 718.93k 639k ++++++36 000
14 INTERACTIVE BROKERS LLC 0.52% 709.25k 630.4k
15 HELLERUD TOR 0.49% 678.77k 603.4k
16 NORDNET BANK AB 0.44% 606.29k 538.9k -14 725
17 SKANDINAVISKA ENSKILDA BANKEN AB 0.41% 562.5k 500k
18 SKIHUS AS 0.34% 469.39k 417.2k
19 TRIVON AS 0.33% 450k 400k
20 HØGNABBEN AS 0.31% 426.38k 379k
21 MORTEN CARLSON AS 0.30% 417.18k 370.8k
22 JOHNSEN HARALD MORTEN 0.30% 410.63k 365k
23 M PAULEN HOLDING AS 0.30% 408.04k 362.7k
24 HALDEN THORLEIF 0.29% 393.75k 350k ++++++++++50 000
25 GILBO ODD AUGUST 0.28% 381.07k 338.7k
26 KLAVENESS MARINE FINANCE AS 0.27% 364.06k 323.6k
27 JØRSTAD JAN-HENRIK 0.25% 346.52k 308k
28 WINGE JØRGEN 0.25% 337.97k 300.4k
29 NORDEA BANK ABP 0.25% 337.84k 300.3k
30 THIRTY EIGHTH SEPELDA P/L ATF FINC 0.25% 337.5k 300k
31 RISA FORVALTNING AS 0.23% 315k 280k
32 PROFECTUS-INVEST AS 0.22% 308.89k 274.6k
33 LAM CONG LUONG 0.22% 303.75k 270k
34 KOLBEINSHAVN HELGE 0.21% 292.5k 260k
35 SPERRE LARS PEDER SØRVAAG 0.21% 285.25k 253.6k
36 GRINDVOLL IDAR ANDERSEN 0.21% 284.52k 252.9k
37 HERSETH AS 0.19% 258.75k 230k
38 MIDDELBOE AS 0.19% 258.75k 230k
39 TEIEN OLE ANDREAS 0.19% 256.33k 227.8k
40 HØSE AS 0.17% 238.44k 212k
41 JANSSON KRISTIAN HENRY 0.17% 234.28k 208.3k
42 SWEDBANK AB 0.17% 227.7k 202.4k
43 SIX SIS AG 0.17% 226.7k 201.5k
44 TANGERUD KJETIL KEITH 0.16% 225.52k 200.5k
45 LBM INVEST AS 0.16% 225k 200k
46 REINERTSEN INGE 0.16% 225k 200k
47 T.M.C INVEST AS 0.16% 225k 200k
48 CARLSON MORTEN ALF 0.15% 210.6k 187.2k
49 BRAATHEN JØRGEN HELLUM 0.15% 208.17k 185k
50 AAS GAUTE 0.15% 206.39k 183.5k
51 Other investors 16.62% 22.83m 20.29m -71 300
TLO
24.05.2024 kl 14:07
1412
Noen som vet når man oppdaterer dette i markedet. Skal det bli en emisjon så er det vel viktig at alle er like informert som en eventuelt en investor er det.
Sukiyaki
17.04.2024 kl 21:18
1603
Gode nyheter??? Kaller ikke dette gode nyheter. Lykke til med henting av penger. Tror mange har brent sine fingre i dette tapssluket og de få som har vært med hele veien, har et vanvittig papirtap.
Gullhaugen
17.04.2024 kl 13:38
1703
Dette var gode nyheter. Ut med Kinamann og inn med et stort seriøst selskap. God lesning : https://news.cision.com/circio/r/circio-announces-in-vivo-proof-of-concept-for-its-circvec-circular-rna-platform-technology-and-reinf,c3962653
Martin10
05.09.2023 kl 14:39
2422
· ONCOS-102 combined with chemotherapy demonstrated 34.1% overall survival (OS)
rate at 30 months in first line patients, compared to 0% in the chemotherapy
-only group
· ONCOS-102 promoted robust immune responses, including an association between
T-cell infiltration and patient survival
Oslo, Norway, 4 September 2023- Circio Holding ASA (OSE: CRNA), a biotechnology
company developing novel circular RNA and immunotherapy medicines, today
announces that the completed phase 1/2 trial of ONCOS-102 in combination with
Standard of Care (SoC) chemotherapy in malignant pleural mesothelioma (MPM) has
been published in the Journal for ImmunoTherapy of Cancer (JITC), the
prestigious immunology journal of the Society for Immunotherapy of Cancer
(SITC).
The study was a randomized phase 1/2 trial adding ONCOS-102 to SoC chemotherapy
(pemetrexed/cisplatin) in first and later line MPM to assess safety, immune
activation and clinical efficacy in a total of 31 patients. The ONCOS-102 and
SoC combination showed a favorable safety profile, robust immune responses in
injected tumors and a signal of clinical benefit. In first line patients, the OS
rate at 30 months was 34.1% for ONCOS-102-treated patients, which is a clear
improvement over the first-line SoC-only control group where the OS rate was 0%.
Title of publication: ONCOS-102 plus pemetrexed and platinum chemotherapy in
malignant pleural mesothelioma: a randomized phase 2 study investigating
clinical outcomes and the tumor microenvironment
For the full publication, please see link:
https://jitc.bmj.com/content/11/9/e007552
Margrethe Sørgaard, VP and Head of Clinical at Circio, said: "Mesothelioma
remains a challenging disease with poor prognosis and few available treatment
options. In this exploratory trial, ONCOS-102 demonstrated a clear signal of
clinical benefit for this underserved patient group, particularly in an early
treatment setting. Importantly, the study also showed that ONCOS-102 can be
safely and effectively combined with chemotherapy and drive robust immune
activation in an immunologically cold tumor type, thereby demonstrating the
versatility of the product and expanding future development opportunities."
***
For further information, please contact: Legger ut hele meldingen som aqksjonærene fikk i går. Til orientering for interesserte.
Martin10
04.09.2023 kl 17:48
2572
Noen fagfolk her inne som kan fortelle nærmere hva dagens melding innebærer. Var dette et gjennombrudd? Veien videre.
Martin10
04.09.2023 kl 14:04
2644
Og dermed spratt aksjen opp 14,3%.
Redigert 04.09.2023 kl 14:08
Du må logge inn for å svare
Martin10
04.09.2023 kl 11:05
2710
Selskapet børsmelder i dag.
· ONCOS-102 combined with chemotherapy demonstrated 34.1% overall survival (OS)
rate at 30 months in first line patients, compared to 0% in the chemotherapy
-only group
· ONCOS-102 promoted robust immune responses, including an association between
T-cell infiltration and patient survival
Bør være av interesse for aksjonærer og investorer.
· ONCOS-102 combined with chemotherapy demonstrated 34.1% overall survival (OS)
rate at 30 months in first line patients, compared to 0% in the chemotherapy
-only group
· ONCOS-102 promoted robust immune responses, including an association between
T-cell infiltration and patient survival
Bør være av interesse for aksjonærer og investorer.
Sukiyaki
28.08.2023 kl 13:14
2874
Beklager men ingen har troen på dette selskapet lenger. Troen på Julenissen har større oppslutning enn dette selskapet CRNA eller Targovax som det het tidligere.
Ledelsen trodde kanskje at et navneskifte skulle hjelpe?
Spennende ting på gang, er det om de overlever og kan fortsette festen med å grafse til seg penger fra aksjonærene?
Redigert 28.08.2023 kl 13:16
Du må logge inn for å svare
thoran
24.08.2023 kl 03:57
3053
Generelt er slike aksjer risikable og da snakker jeg også av egen erfaring. Men skulle de lykkes er det stort potensiale for dette selskapet og eierne. Selvsagt er det den mulige oppside som er attraktiv i slike selskap. Mener Circio Holding kan inneha nok kvaliteter/ressurser til å lykkes. Her er det positive nyheter som gjelder i hvert fall i første omgang. Selvsagt er økonomien viktig, men den vil bedres betydelig hvis de skulle lykkes med noen av deres studier.